CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 51 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6 | +50.0% | 199 | 0.0% | 0.00% | – |
| Q2 2023 | $4 | +33.3% | 199 | 0.0% | 0.00% | – |
| Q1 2023 | $3 | -25.0% | 199 | 0.0% | 0.00% | – |
| Q4 2022 | $4 | -99.9% | 199 | 0.0% | 0.00% | – |
| Q3 2022 | $4,000 | 0.0% | 199 | 0.0% | 0.00% | – |
| Q2 2022 | $4,000 | +33.3% | 199 | +50.8% | 0.00% | – |
| Q1 2022 | $3,000 | -25.0% | 132 | 0.0% | 0.00% | – |
| Q4 2021 | $4,000 | +33.3% | 132 | 0.0% | 0.00% | – |
| Q3 2021 | $3,000 | +200.0% | 132 | +112.9% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 62 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 62 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | -50.0% | 62 | -59.5% | 0.00% | – |
| Q3 2019 | $2,000 | -50.0% | 153 | 0.0% | 0.00% | – |
| Q2 2019 | $4,000 | +33.3% | 153 | 0.0% | 0.00% | – |
| Q1 2019 | $3,000 | -57.1% | 153 | -30.5% | 0.00% | – |
| Q4 2018 | $7,000 | – | 220 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,030,616 | $31,028,000 | 6.04% |
| 5AM Venture Management, LLC | 1,362,286 | $20,816,000 | 3.75% |
| Burrage Capital Management LLC | 272,393 | $4,162,000 | 3.37% |
| Altium Capital Management LP | 361,930 | $5,530,000 | 1.54% |
| Vivo Capital, LLC | 2,214,138 | $33,832,000 | 1.19% |
| Bain Capital Life Sciences Investors, LLC | 1,071,428 | $16,371,000 | 0.93% |
| Perceptive Advisors | 3,659,381 | $51,606,000 | 0.65% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,154,000 | 0.50% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,003,688 | $30,616,000 | 0.45% |
| Opaleye Management Inc. | 188,000 | $2,873,000 | 0.42% |